SEATTLE, WASHINGTON--(Marketwired - Oct. 15, 2015) - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSX VENTURE:VPT) announces that at its Annual General Meeting on October 13, 2015 the shareholders elected Dr. George Adams, Mr. Danny Dalla-Longa, Dr. Alan Rabinowitz and Mr. Treuman Katz as Directors of the Company. They further approved the Incentive Stock Option plan and gave authority to the Board of Directors to undertake a share consolidation if it deems the consolidation is in the best interests of Ventripoint. BDO was appointed as auditors of the Company for the next year.
In addition, on September 30, 2015 the Company retained the services of Renmark Financial Communications Inc. ("Renmark") to handle its investor relations activities. "We are pleased to announce that we have selected Renmark to reinforce Ventripoint's profile in the financial community and enhance the visibility of our project portfolio. We chose Renmark because its standards and methodologies fit best with the message we wish to communicate to the investing public," noted Dr. George Adams, President and Chief Executive Officer of Ventripoint.
Founded in 1999 by its sole owner, Mr. Henri Perron, Renmark is based in Montreal, Quebec and is a leading full-service investor relations firm representing publicly traded companies listed on all major North American stock exchanges.
In consideration of the services to be provided, the Company has agreed to pay a monthly retainer of $5,000 for a term of six months, starting October 1st, 2015, to Renmark. Renmark Financial Communications does not have any interest, directly or indirectly, in Ventripoint Diagnostics Ltd. or its securities, or any right or intent to acquire such an interest.
About Ventripoint Diagnostics Ltd.
Ventripoint has created tools to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate tool for measuring right ventricle heart function. The Corporation has a suite of applications for all major heart diseases and imaging modalities including congenital heart disease, left or right heart failure and normal hearts - a multi-billion dollar market potential.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.